Montelukast drug interactions

From Pubdrug

Contents 1 Drug-drug interactions 2 Drug-food/drug-herb interactions 3 References

This page has been completed and reviewed for accuracy. You are reading a certified PubDrug document. This document is complete and accurate to the best of the knowledge of the author and reviewer. This document cannot be edited without being unlocked by a PubDrug admin. Edits or updates may be recommended under the Discussion tab. Authored by: Aahynes 20:00, 22 February 2007 (PST) Certified by: Khlee3 13:48, 25 February 2007 (PST)

Back to monograph page

Drug-drug interactions

Severity level	Drug and description of interaction
4	None known
3	None known
2	barbiturates, carbamazepine, fosphenytoin, phenytoin, rifabutin, rifampin, rifapentine, troglitazone: CYP 3A4 inducers may decrease the plasma concentrations of montelukast due to induction of the CYP3A4 isoenzyme, leading to therapeutic failure.[1][2][3][4] prednisone: Montelukast may increase the risk of edema associated with prednisone therapy.[5] repaglinide, rosiglitazone: In vitro studies suggest that montelukast is a potent CYP 2C8 inhibitor, which may lead to higher concentrations of these drugs and thus, increased side effects.[6][7]
1	cerivastatin, paclitaxel: In vitro studies suggest that montelukast is a potent CYP 2C8 inhibitor, which may lead to higher concentrations of these drugs and thus, increased side effects.[1][8]

Drug-food/drug-herb interactions

Severity level	Drug and description of interaction
4	None known
3	St John's Wort: CYP 3A4 inducers may decrease concentrations of montelukast, leading to therapeutic failure[9]
2	None known
1	None known

References

1. ↑ ^1.0 1.1 Singulair® (montelukast) package insert. Whitehouse Station, NJ: Merck & Co, Inc.; 2005 Sep.
2. ↑ Cerebyx® (fosphenytoin sodium) package insert. New York, NY: Parke-Davis; 2002 Jun.
3. ↑ Priftin® (rifapentine) package insert. Kansas City, MO: Aventis Pharmaceuticals Inc.; 2003 Feb
4. ↑ Rezulin® (troglitazone) package insert. Morris Plains, NJ: Parke-Davis; 1999 June.
5. ↑ Geller M, Geller M. Marked peripheral edema associated with montelukast and prednisone. Annals of Internal Medicine. 2000 Jun 6;132(11):924.
6. ↑ Bidstrup TB, Bjornsdottir I, Sidelmann UG, et al. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol 2003;56:305—14.
7. ↑ Avandia® (rosiglitazone) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2003 Mar
8. ↑ Taxol® (paclitaxel) package insert. Princeton, NJ: Bristol-Meyers Squibb Oncology; 2003 March.
9. ↑ Gordon JB. SSRIs and St.John's Wort: possible toxicity? American family physician. 1998 Mar 1;57(5):950-53